Key Players
Competitive Landscape
Endovascular surgical robotics market includes magnetic-navigation companies, mechanical robotic-system suppliers, single-use platform developers and remote neurovascular companies. Stereotaxis and Robocath are offering magnetic and mechanical systems, whereas Microbot Medical is focusing on single-use peripheral navigation. Sentante has started vascular and interventional radiology rollout in Europe. XCath, Nanoflex Robotics, Remedy Robotics and Siemens Healthineers are developing remote or autonomous stroke systems. Hospitals are examining approved indication, compatible devices, operator control and local service before selecting a robotic platform. Availability of training and instrument supply is also expected to influence company preference.
During 2025 and 2026, some of the key players increased focus on commercial release and wider hospital access. Microbot Medical entered an agreement in June 2026 for access to more than 2,000 U.S. government healthcare facilities. Sentante started European commercial rollout in August 2026 after receiving CE Mark approval. Stereotaxis reported robotic catheter revenue above USD 1.0 million and the first U.S. GenesisX purchase in August 2026. Increasing product availability, sales coverage and procedure-linked catheter use is expected to increase competition during the forecast period.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| June 2026: Microbot Medical Inc. entered a manufacturing letter of agreement with Sanmina. [24] | Increasing manufacturing capacity supports availability of single-use robotic units. | Companies are expanding contract manufacturing for robotic devices. | Additional production can support commercial supply as procedure demand increases. |
| August 2026: Sentante UAB announced the start of European commercial rollout in vascular surgery and interventional radiology. [20] | Commercial rollout supports use in vascular surgery and interventional radiology. | Companies are entering peripheral procedures before remote stroke applications. | Increasing routine use can create repeat demand for robotic instruments and services. |
| August 2026: ARPA-H named Siemens Healthineers AG among funded endovascular robotics teams. [5] | Remote robotics can support specialist stroke treatment at prepared hospitals. | Government funding is supporting autonomous endovascular navigation research. | Program development can create future opportunities for autonomous stroke systems. |
Stereotaxis, Robocath, Microbot Medical and Sentante are participating through approved or commercially released robotic systems. XCath, Nanoflex Robotics, Remedy Robotics and Siemens Healthineers remains focused on remote or autonomous neurovascular development. Difference in product indication, catheter compatibility and service coverage provides separate market positions to these companies.
Source: Future Market Insights, Endovascular Surgical Robotics Market Report, 2026-2036.
Companies having approved products, compatible instruments and trained service teams are expected to receive higher preference among hospitals. Development-stage companies will require additional clinical and regulatory evidence before wider commercial participation.
How do the profiled companies differ in competitive positioning?
Stereotaxis offers magnetic navigation, Robocath provides mechanical coronary robotics and Microbot Medical supplies an FDA-cleared single-use peripheral system.
What qualification requirements should buyers examine before choosing a supplier?
Hospitals should examine approved indication, compatible guidewires and catheters, imaging requirement, manual conversion and local technical support before approving a supplier. Availability of training, disposable units and maintenance services are also expected to influence supplier selection.
Which application capabilities are documented rather than assumed?
Stereotaxis has documented magnetic navigation and a MAGiC ablation catheter, whereas Microbot Medical has FDA clearance for peripheral navigation. Sentante has CE Mark approval for vascular procedures, while XCath and Remedy Robotics are progressing remote neurovascular platforms.
How should geographic reach be interpreted for these companies?
Microbot Medical reports commercial use in the USA, while Sentante has started rollout in Europe. Robocath reports use of R-One in European and Chinese hospitals, whereas remote neurovascular companies have limited clinical or development-stage reach.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Stereotaxis, Inc. | Magnetic navigation systems and robotic catheter products. | In January 2026, Stereotaxis announced U.S. authorization of the MAGiC magnetic ablation catheter for specified supraventricular tachycardias.[21] |
| Nanoflex Robotics AG | Magnetic telerobotics system for neurovascular procedures. | In June 2026, Nanoflex Robotics announced selection for EIC Accelerator financing for clinical validation and product development.[22] |
| Remedy Robotics, Inc. | Remote neurovascular robotic platform under development. | In October 2025, Remedy Robotics announced a partnership with SVIN Mission Thrombectomy for N1 development and testing.[23] |
Research Methodology
The companies included in the report represents current market structure and does not indicate a market-share ranking. Company inclusion is based on public evidence for robotic systems, compatible devices, clinical activity, product approval and remote navigation development. Regulatory records and company announcements are used for reviewing product status. Commercial systems, investigational platforms and preclinical programs are considered separately. Market values, segment shares and country forecasts are analytical estimates. Research grants, unrelated imaging systems, hospital procedure fees and soft-tissue surgical robots are excluded from the market.
